Ocugen IncNASDAQ:OCGN
- LAST PRICE1.0150
- TODAY'S CHANGE (%)0.0296 (3.0039%)
- Bid / Lots1.0100/ 62
- Ask / Lots1.0200/ 152
- Open / Previous Close0.9904 / 0.9854
- Day Range
- 52 Week Range
- Volume1,027,113
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCGN |
|---|---|---|
| 09:32 ET | 25301 | 0.9949 |
| 09:34 ET | 830 | 0.9993 |
| 09:36 ET | 5411 | 1.0002 |
| 09:38 ET | 8317 | 1.0037 |
| 09:39 ET | 4399 | 1.01 |
| 09:41 ET | 19338 | 1.015 |
| 09:43 ET | 10642 | 1.0189 |
| 09:45 ET | 12616 | 1.005 |
| 09:48 ET | 50433 | 1.0175 |
| 09:50 ET | 208889 | 1.05 |
| 09:52 ET | 115225 | 1.0347 |
| 09:54 ET | 29600 | 1.023 |
| 09:56 ET | 17567 | 1.03 |
| 09:57 ET | 5184 | 1.03 |
| 09:59 ET | 4557 | 1.0294 |
| 10:01 ET | 61950 | 1.015 |
| 10:03 ET | 4803 | 1.01 |
| 10:06 ET | 5828 | 1.015 |
| 10:08 ET | 2975 | 1.015 |
| 10:10 ET | 5200 | 1.015 |
| 10:12 ET | 739 | 1.015 |
| 10:14 ET | 2438 | 1.0195 |
| 10:15 ET | 11514 | 1.015 |
| 10:17 ET | 3405 | 1.015 |
| 10:19 ET | 2871 | 1.0192 |
| 10:21 ET | 1400 | 1.02 |
| 10:24 ET | 1679 | 1.015 |
| 10:26 ET | 4022 | 1.02 |
| 10:28 ET | 9228 | 1.01 |
| 10:30 ET | 447 | 1.015 |
| 10:32 ET | 18926 | 1.015 |
| 10:33 ET | 46391 | 1.03 |
| 10:35 ET | 2105 | 1.024 |
| 10:37 ET | 7074 | 1.025 |
| 10:39 ET | 2319 | 1.0289 |
| 10:42 ET | 46586 | 1.015 |
| 10:44 ET | 22242 | 1.015 |
| 10:46 ET | 1049 | 1.02 |
| 10:48 ET | 6204 | 1.015 |
| 10:50 ET | 6804 | 1.02 |
| 10:51 ET | 3170 | 1.02 |
| 10:53 ET | 2161 | 1.02 |
| 10:55 ET | 1600 | 1.015 |
| 10:57 ET | 1800 | 1.02 |
| 11:00 ET | 5791 | 1.0115 |
| 11:02 ET | 6099 | 1.015 |
| 11:04 ET | 700 | 1.015 |
| 11:06 ET | 3503 | 1.0114 |
| 11:08 ET | 82854 | 1.015 |
| 11:09 ET | 24359 | 1.015 |
| 11:11 ET | 1899 | 1.014 |
| 11:13 ET | 12338 | 1.01 |
| 11:15 ET | 6049 | 1.02 |
| 11:18 ET | 1800 | 1.015 |
| 11:20 ET | 1094 | 1.015 |
| 11:22 ET | 15285 | 1.015 |
Yesterday
Ocugen, Inc. (OCGN) Shareholder Notice: Grabar Law Office Investigates Claims on Your Behalf, from 7:06AM ET on Thursday Sep 26, 2024 by Dow Jones
7:06AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 24, 2024
Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference, from 7:30AM ET on Tuesday Sep 24, 2024 by Dow Jones
7:30AM ET on Tuesday Sep 24, 2024 by Dow Jones
Sep 20, 2024
Shareholder Alert: Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Ocugen, Inc. (OCGN), from 9:52AM ET on Friday Sep 20, 2024 by Dow Jones
9:52AM ET on Friday Sep 20, 2024 by Dow Jones
Sep 17, 2024
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm, from 8:00AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:00AM ET on Tuesday Sep 17, 2024 by Dow JonesGRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF LONG-TERM SHAREHOLDERS OF OCUGEN, INC. (NASDAQ: OCGN), from 6:06AM ET on Tuesday Sep 17, 2024 by Dow Jones
6:06AM ET on Tuesday Sep 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ocugen Inc | 283.7M | -5.7x | --- |
XOMA Royalty Corp | 298.2M | -11.7x | --- |
PepGen Inc | 283.2M | -2.7x | --- |
Jasper Therapeutics Inc | 284.6M | -3.6x | --- |
Solid Biosciences Inc | 280.6M | -2.2x | --- |
Abeona Therapeutics Inc | 256.9M | -2.9x | --- |
Company Information
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
Contact Information
- Headquarters
- 11 GREAT VALLEY PARKWAYMALVERN, PA, United States 19355
- Phone
- 484-328-4701
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Shankar Musunuri
- Chief Accounting Officer, Controller
- Michael Breininger
- Chief Scientific Officer, Executive Officer, Head of Research and Development
- Arun Upadhyay
- Chief Medical Officer
- Huma Qamar
- Independent Director
- Kirsten Castillo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $283.7M |
|---|---|
Revenue (TTM) | $8.2M |
Shares Outstanding | 287.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.72 |
EPS | $-0.18 |
Book Value | $0.16 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 34.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -631.33% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
